Mochida Pharmaceutical Adopts British Inpharmatica's In-silico ADME Suite, Admensa Interactive.Tokyo, Japan, Oct 15, 2005 - (JCNN JCNN Japan Corporate News Network ) - PharmaDesign announced on October 11 that Mochida Pharmaceutical has signed a licensing agreement with Inpharmatica, a UK drug discovery firm, for Admensa Interactive, Inpharmatica's proprietary in-silico suite of predictive drug absorption, distribution, metabolism and excretion excretion, process of eliminating from an organism waste products of metabolism and other materials that are of no use. It is an essential process in all forms of life. In one-celled organisms wastes are discharged through the surface of the cell. (ADME ADME Absorption, Distribution, Metabolism, and Excretion ADME Association of Destination Management Executives ADME Active Duty Medical Extension ) models and compound prioritization tools. Mochida Pharmaceutical is the second such Japanese company that introduces Inpharmatica's Admensa Interatctive suite. With this move, Mochida will be able to accelerate its drug discovery process and reduce relative costs. PharmaDesign, a Tokyo-based venture company specializing in genomic drug discovery, is a sales and marketing partner of Inpharmatica in Japan. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion